92 results about "Tetrahydrocannabinol" patented technology

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking immunosuppressant drugs. In particular the immunosuppressant drug is a calcineurin inhibitor. More particularly the immunosuppressant drug is tacrolimus. Where the CBD is used in combination with an immunosuppressant drug, caution should be taken. For example, the dose of either the CBD and / or the immunosuppressant drug may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

A method is provided for the synthesis of (-)-trans-Δ9-tetrahydrocannabivarin (Δ9-THCV) and analogs thereof such that in the reaction product, the molar ratio of the Δ9 isomer to incidentally formed Δ8 isomers is greater than 4:1. Synthesis is carried out by combining a selected cannabinoid reactant, e.g., cannabidivarin (CBDV) or an analog thereof, with an acid in a solvent for the cannabinoid reactant, wherein the acid comprises (i) a Lewis acid having an acid softness index value in the range of -10 ΔG0 f, M n+ to ‑150 ΔG0 f, M n+, (ii) a Brønsted acid having a pKa in the range of -4.0 to +4.0, or (iii) a combination of (i) and (ii), under reaction conditions comprising a reaction temperature in the range of ‑0 °C to 25 °C and a reaction time in the range of 1 hour to 24 hours. The reaction is thereafter quenched with base and the solvent removed, wherein the crude reaction product so provided may be purified, e.g., chromatographically purified. Also provided is a method for synthesizing Δ9-THCV that further includes synthesis of the cannabinoid reactant. The invention additionally provides novel cannabinoid compositions that may be synthesized using the aforementioned methodology.

A transdermal delivery composition for the delivery to skin and the penetration of the skin includes: (a) a therapeutic effective amount of a cannabinoid mixture, wherein the cannabinoid mixture comprises cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) at a weight ratio of about 1:20 to about 20:1; (b) a hydrophilic polymer / hydrophobic polymer adduct in an amount sufficient to hold the cannabinoid composition and provide a sustain release of the cannabinoid mixture after application to skin tissue over a time period of at least 6 hours; (c) a penetrant component in an amount sufficient to assist with a transdermal penetration of the cannabinoid mixture through skin tissue once the composition has been applied to skin tissue; (d) a surfactant component in an amount sufficient to stabilize the polymer adduct and release the cannabinoid mixture from the transdermal delivery composition upon application to skin tissue; and (e) at least about 70 wt. % water. A method of application of a transdermal delivery composition to skin tissue includes applying the transdermal delivery composition to skin tissue and spreading the composition to form a film on the skin tissue. A method for formulating a transdermal delivery composition based on a desired penetration weight ratio of CBD to THC through skin tissue includes selecting a formulation weight ratio of CBD to THC for formulating the composition, wherein the weight ratio is determined by multiplying the desired penetration weight ratio of CBD to THC by a CBD / THC delivery factor, wherein the CBD / THC delivery factor.

Compositions including Δ-9-tetrahydrocannabinol (THC) and a carbonic andydrase inhibitor and methods of using these compositions for the treatment of obstructive sleep apnoea (OSA). The treatment method also includes administering dronabinol and acetazolaminde and combinations thereof to a subject in need thereof.

The invention relates to a method for specifically detecting tetrahydrocannabinol and hydride thereof by utilizing bridged beta-cyclodextrin, and belongs to the technical field of analysis and detection of supramolecular materials. The method comprises the following steps: firstly, combining 1, 6-hexamethylenediamine bridged bis-beta-cyclodextrin with an indicator to form a supramolecular probe; in a buffer system with a pH value of 9-11, tetrahydrocannabinol or a hydride thereof specifically competes to be combined with a cavity and displaces an indicator by utilizing a synergistic inclusion effect of a bridging subject and dissociation difference of guest molecules, so that the system is subjected to fluorescence quenching or color change, and a structural analogue cannabidiol does not generate obvious interference. The method solves the problems that the sensitivity is low and cannabidiol cannot be effectively distinguished in the prior art through cooperation of specific main body construction and environment regulation, has the advantages of being rapid in detection, high in specificity, high in accuracy and the like, and is suitable for environment monitoring and field screening.

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. The compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as the major components therein, which may be isolated, purified or extracted from cultivars and blended together. The compositions include CBD, CBG and THC in certain ratios, formulated for the use in the treatment of PTE.

The present invention relates to novel cannabinoids 1 and 2 synthesized from simple starting materials using a cascade sequence of allylic rearrangement, aromatization, and further cyclization that is highly stereoselective and regioselective for tetracyclic cannabinoids. The synthesized cannabinoids can be obtained more easily at a higher purity level than cannabinoids isolated or synthesized by known methods. Cannabinoid 2 is obtained containing very low levels of unwanted isomer cannabinoids, such as Δ8-tetrahydrocannabinol. While they are easily synthesized by the new methodology, analogs with modifications of aromatic ring substituents would be much more difficult to produce from any of the components of cannabis oil. Novel compounds of formulas 3, 4, 5, and 6 are disclosed as intermediates for the synthesis of cannabinoids of formulas 1 and 2.

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking caffeine. Where the CBD is used in combination with caffeine, caution should be taken. For example, the dose of either the CBD and / or caffeine may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 95% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

In one aspect, the disclosure relates to the use of negative allosteric modulators (NAMs) of cannabinoid receptor 1 (CB1) and pharmaceutical compositions comprising the same in methods of treating or preventing diseases or disorders including substance abuse, anxiety, pain, obesity, cancers, neurodegenerative disorders, and central nervous system (CNS) disorders. In one aspect, the NAM can be selected from H4-CBD or CBDP. In some aspects, the pharmaceutical compositions additionally include Δ9-tetrahydrocannabinol (THC), and the NAMs of CB1 reduce or eliminate unwanted neurological side effects of THC while preserving its disease- and symptom-mitigating effects.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

The present disclosure may broadly provide composition for applying to food comprising a cannabidiol (CBD) having a purity greater than 90% and a tetrahydrocannabinol (THC) having a purity greater than 90% at a ratio of CBD:THC of about 5:1 to about 80:1, for a combined cannabinoid concentration of up to 15 g / L, a pharmaceutically compatible carrier oil, a pharmaceutically compatible emulsifier system, greater than 60% w / v water, and the composition having a viscosity of 500 to 5,000 cP at 21°C, a pH of between 4-7 and being in the form of an oil-in-water nanoemulsion.

This invention provides methods for the synthesis of cannabidiol and its analogues, as well as related compounds, formulations, and methods of use. [Solution] Methods are provided for the synthesis of oliveitol, oliveitol analogs, cannabidiol (CBD), CBD analogs, and other cannabinoids. One method uses phloroglucinol or phloroglucinol analogs as starting materials. The synthesis is stereospecific, efficient, selective, cost-effective, and THC((-)-trans-Δ 9 There is little to no possibility of generating (tetrahydro-cannabinol) or any other psychoactive by-products. Shortened synthesis is also provided, as well as new cannabinoids, pharmaceutical formulations, and methods of use.

The present invention relates to a process for purifying cannabinoids, specifically cannabidiol, in a substantially pure form from herbal material. This process involves a sequence of purification steps including winterization, co-crystallization, dissociation, decarboxylation, and crystallization. Cannabidiol is purified from an extract of herbal material containing approximately 50-70% cannabidiolic acid (CBDA) and 10-20% cannabidiol (CBD), along with other cannabinoids. The substantially pure form of cannabidiol can be used in medicaments for treating various diseases or conditions. The invention also relates to co-crystals of L-proline and cannabidiolic acid and their use in obtaining substantially pure cannabidiol free from tetrahydrocannabinol (THC).

Provided are methods, devices, and systems for identifying the concentration of delta-9-tetrahydrocannabinol (Δ-9 THC) in a given sample. The system allows for in situ formation of a chromophore eliminating the use of chloroform, wherein said chromophore absorbance spectra is measured using a spectroscopy method within a light wavelength range. The system allows for calculating the concentration of Δ-9 THC using the linear relationship between the Δ-9 THC level and the intensity of the color change in the present tester. Said linear relationship is obtained because the tester of the present disclosure allows the chromophore formation reaction go to completion.

Methods are provided for the synthesis of cannabinoids, including cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidivarin (CBDV), cannabidibutol (CBD-C4), dihydrocannabidiol (DCBD), tetrahydrocannabivarin (THCV), analogs thereof, and precursors to the foregoing. One method employs phloroglucinol or a phloroglucinol analog as a starting material. The syntheses are stereospecific, efficient, selective, and cost-effective, with little or no potential for generation of THC ((−)-trans-Δ9-tetrahydro-cannabinol) or any other psychoactive side product. Telescoped syntheses are also provided, as are new cannabinoids, pharmaceutical formulations, and methods of use.

Disclosed is a transdermal therapeutic system comprising an active agent impermeable backing layer, at least one adhesive layer comprising at least 70% by weight of at least one polysiloxane polymer, at least one tetrahydrocannabinol (THC) and at least one solubilizer, and optionally a protective layer for removal before use, a method for its preparation and its use as a medicament.

A device for detecting the presence of past smoking events within an enclosure is provided. The base filter will react to byproducts including tobacco and tetrahydrocannabinol (THC) and will then activate the filter base chemicals to register the smoking events. The device will be facilitated by a protecting case which houses a filter. The design will also interact with the ambient environment and provide ventilation to the filter while monitoring and detecting smoking events.

This invention discloses a quantitative analysis method for tetrahydrocannabinol (THC) and cannabidiol (CBD). The analytical method includes the following steps: injecting the sample into a gas chromatograph, subjecting it to programmed temperature rise, and detecting the total content of CBD and / or THC using an external standard method; wherein the injection port temperature of the gas chromatograph is 200–300°C; the programmed temperature rise is from 150°C to 280°C; and the programmed temperature rise rate is 10–30°C / min. This analytical method can easily and accurately detect the total amount of usable THC and CBD in cannabis flower and leaf raw materials or extracts. Firstly, no special pretreatment of the sample is required; only a certain organic solvent is needed to achieve complete and effective extraction and simple filtration of the cannabinoid components in the sample. Secondly, no THCA and CBDA reference standards are needed to detect the actual total amount of THC and CBD. Thirdly, the quantitative analysis results are accurate and reliable.

The present invention relates to a composition comprising delta-9-tetrahydrocannabinol (THC), alpha-bisabolol, guaiol, beta-caryophyllene and at least one terpene selected from the group consisting of linalool, alpha-humulene, nerolidol, caryophyllene oxide, alpha-pinene, camphene, beta-pinene, beta-myrcene, limonene, eucalyptol, ocimene, gamma-terpinene, terpinolene, alpha-terpinene, para-cymene, isopulegol and geraniol. The invention also relates to a pharmaceutical formulation comprising such composition. The pharmaceutical formulation according to the present invention may be used in medicine, specifically in the treatment and / or prevention of diseases associated with pain such as chronic cancer pain, somatic pain, visceral pain, central neuropathic pain, peripheral neuropathic pain or complex pain syndromes.

There is disclosed a composition comprising delta-9-tetrahydrocannabinol, cannabidiol, cannabigerol and a terpene component.

Compositions for the extended release of one or more cannabinoids, in which the compositions comprise a population of particles. Each particle may comprise the one or more cannabinoids, one or more drug-releasing agents, one or more surfactants, and a core. The core may comprise a porous bead. The one or more cannabinoids may comprise Δ9-tetrahydrocannabinol, cannabidiol, or a combination thereof.

The use of a small molecule compound in increasing the content of cannabidiol and tetrahydrocannabinol in cannabis. Experiments verify that a low concentration of RPS-1 can increase the content of CBD and THC in planted cannabis and, in practical production and use, reduce the production costs of CBD and THC. RPS-1 is exogenously sprayed and flexibly applied. The method does not need to change the variety and genetic background of cannabis, and can be applied to cannabis of all varieties.

Systems and methods for detecting Δ9-tetrahydrocannabinol (Δ9-THC) are described. In many embodiments, the detection of Δ9-THC can be achieved by oxidizing Δ9-THC to corresponding oxidized products. The oxidation of Δ9-THC can be achieved chemically or electrochemically. The oxidized products of Δ9-THC can exhibit different photophysical and electrochemical properties compared to Δ9-THC. Many embodiments implement integrating Δ9-THC detection into a multimodal marijuana breathalyzer device.

The present invention describes a method which outlines a process for conversion of CBD to a Δ9-tetrahydrocannabinol (Δ9-THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the Δ9-tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% Δ9-THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce Δ9-THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% Δ9-THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the Δ9-THC using distillation and collecting an essentially pure fraction of Δ9-THC using additional distillation or enrichment form of purification. Included are methods and processes to scale the reaction from the lab to large scale manufacturing. Included are methods for adding a molecule marker to authenticate high purity Δ9-THC products. Formulations and uses for pharmaceuticals, nutraceuticals, food products, and topicals are also provided.

The present disclosure relates to the to the transdermal administration of cannabinoids, such as, CBD and / or THC, and derivatives of these compounds, for the treatment and / or prevention and / or control of chronic pain.

The present invention relates to a solid oral pharmaceutical for Tetrahydrocannabinol (API) or any other Cannabinoid (API) with a novel, well defined method to enhance solubility of active pharmaceutical ingredients (API) with low solubility in aqueous media and use those enhanced API in a new approach of preparing modified and / or sustained release pharmaceutical formulation for API which are regularly not suitable for sustained release formulations because of their low solubility. This invention is applicable for small molecule API (molecular weight < 1000) for which the solubility can be enhanced by formation of a e.g., Cyclodextrin Complex regardless which Cyclodextrin or derivate thereof is employed according to the method described in this invention. Tetrahydrocannabinol and other Cannabinoids can be found in a wide range of indications like pain relief, insomnia, anti- depression and others.

Cannabinoid compositions formulated for use in the treatment of post-traumatic epilepsy (PTE) are disclosed. These compositions include cannabidiol (CBD), cannabigerol (CBG), and tetrahydrocannabinol (THC) as their main components, which may be isolated, purified, or extracted from cultivars and mixed together. The compositions include CBD, CBG, and THC in specific proportions, formulated for use in the treatment of PTE.

A solvent-free method of catalyzing cannabidiol (CBD) to a tetrahydrocannabinol (THC) utilizes a catalyst and carrier oil in combination with extraction techniques to significantly reduce cost and provide high-purity Δ8-THC. Using a non-volatile carrier oil in lieu of a highly-flammable, volatile organic solvent provides a simple process that can be incorporated into an appliance-like device that permits the safe production of Δ8-THC by a typical user in a home environment without the need for complex laboratory apparatus and expensive safety equipment.

The present invention generally relates to methods for producing (a) plant extract(s), preferably a Cannabis plant extract. In particular, the present invention relates to a method for producing a Cannabis plant extract comprising delta-9-tetrahydrocannabinol (THC) from a Cannabis plant comprising the following steps: (a) providing a Cannabis plant which comprises delta-9-tetrahydrocannabinol (THC) in a sufficient amount: (b) trimming and drying the flower material separated from the remaining plant material; and (c) treating the flower material of step (b) with a solvent and separating the Cannabis plant extract comprising delta-9-tetrahydrocannabinol (THC) from the flower material. Furthermore, the invention relates to a Cannabis plant extract comprising delta-9-tetrahydrocannabinol (THC) as produced by / obtainable by the methods described herein. Furthermore, the invention relates to the Cannabis plant extract as produced by / obtainable by the herein described methods for use in medicine. Moreover, the present invention relates to the Cannabis plant extract as produced by / obtainable by the herein described methods for use in the treatment and / or prevention of chronic cancer pain, somatic pain, visceral pain, central neuropathic pain, peripheral neuropathic pain and complex pain syndromes.

A pharmaceutically or nutraceutically acceptable formulation contains a cannabinoid which may be a full spectrum or partial spectrum cannabis extract, tetrahydrocannabinol (THC), an analog of THC, cannabidiol (CBD), an analog of CBD, ora combination thereof and at least one nootropic agent mixed in a carrier medium. A method of making the formulation mixingsaid formula and heatingthe formulation above room temperature until the mixture is homogenous. Additional supplements may be added to each formulation. The formulation may have a carrier medium suitable to be used in capsule, dissolvable tablet, vaporizer, spray, inhaler, tincture, beverage or any other suitable application.